Abstract | BACKGROUND: The manner in which ribavirin (RBV) enhances the antiviral effects of interferon (IFN) against hepatitis C virus (HCV) remains unknown. We investigated whether RBV modifies IFN-stimulated genes (ISGs) in vivo and in vitro. METHODS: We measured the messenger RNA ( mRNA) levels of ISGs in T lymphocytes from patients with HCV infection who were receiving IFN-α therapy with or without RBV. We added RBV and/or IFN-α to a plasmid-based HCV replication system containing a full-length HCV genotype 1a sequence in HepG2 and Huh7 cell lines and the JFH-1 HCV genotype 2a sequence in Huh7 cell lines and measured levels of ISGs and autocrine IFN-β. RESULTS: The expression of protein kinase R and myxovirus resistance A mRNA was enhanced more with IFN-α and RBV than by IFN-α alone in assays in vivo and in vitro. Such enhancement depended on autocrine IFN-β being enhanced by RBV. RBV upregulated interleukin 8 (IL-8) in the absence of IFN-α. The IL-8 upregulation induced by RBV was responsible for the activation of activator protein 1 (AP-1). CONCLUSIONS:
Ribavirin augments the anti-HCV effects of IFN-α induced by ISGs through enhancing autocrine IFN-β. Moreover, RBV can enhance IL-8 through activating AP-1. Improved understanding of ISG modulation by RBV would help to establish a means of eliminating HCV.
|
Authors | Yoshio Tokumoto, Yoichi Hiasa, Kazuhiro Uesugi, Takao Watanabe, Toshie Mashiba, Masanori Abe, Teru Kumagi, Yoshio Ikeda, Bunzo Matsuura, Morikazu Onji |
Journal | The Journal of infectious diseases
(J Infect Dis)
Vol. 205
Issue 7
Pg. 1121-30
(Apr 01 2012)
ISSN: 1537-6613 [Electronic] United States |
PMID | 22357660
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antiviral Agents
- CXCL8 protein, human
- Interferon-alpha
- Interleukin-8
- Ribavirin
- Interferon-beta
|
Topics |
- Adult
- Aged
- Antiviral Agents
(administration & dosage, pharmacology)
- Female
- Gene Expression Profiling
- Hepacivirus
(drug effects, growth & development, immunology)
- Hepatitis C
(drug therapy, immunology, virology)
- Humans
- Interferon-alpha
(administration & dosage, pharmacology)
- Interferon-beta
(biosynthesis, immunology)
- Interleukin-8
(biosynthesis, immunology)
- Male
- Middle Aged
- Ribavirin
(administration & dosage, pharmacology)
- T-Lymphocytes
(immunology)
- Transcriptional Activation
- Virus Replication
(drug effects)
|